CoChat

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on β-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin. RESEARCH DESIGN AND METHODS: In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 ± 10 years; weight, 93 ± 16 kg; A1C, 7.8 ± 0.7%) continued their metformin regimen and received either EXE 10 μg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 μg b.i.d. + ROSI 4 mg b.i.d. (n = 47). Seventy-three participants underwent clamp procedures to quantitate insulin secretion and insulin sensitivity. RESULTS: A1C declined in all groups (P < 0.05), but decreased most with EXE+ROSI (EXE+ROSI, −1.3 ± 0.1%; ROSI, −1.0 ± 0.1%, EXE, −0.9 ± 0.1%; EXE+ROSI vs. EXE or ROSI, P < 0.05). ROSI resulted in weight gain, while EXE and EXE+ROSI resulted in weight loss (EXE, −2.8 ± 0.5 kg; EXE+ROSI, −1.2 ± 0.5 kg; ROSI, + 1.5 ± 0.5 kg; P < 0.05 between and within all groups). At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05). Insulin sensitivity (M value) was significantly higher in EXE+ROSI versus EXE (P = 0.014). CONCLUSIONS: Therapy with EXE+ROSI offset the weight gain observed with ROSI and elicited an additive effect on glycemic control with significant improvements in β-cell function and insulin sensitivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1521

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Glucose and insulin concentrations during the meal challenge test and insulin concentrations during the hyperglycemic clamp before (■, broken line) and after (○, solid line) treatment with EXE, EXE+ROSI, or ROSI. Arrows indicate time of arginine stimulation (ARG) during the hyperglycemic clamp. Data are presented as LS means ± SE for the meal challenge test and LS means for the hyperglycemic clamp.
Figure 1 Glucose and insulin concentrations during the meal challenge test and insulin concentrations during the hyperglycemic clamp before (■, broken line) and after (○, solid line) treatment with EXE, EXE+ROSI, or ROSI. Arrows indicate time of arginine stimulation (ARG) during the hyperglycemic clamp. Data are presented as LS means ± SE for the meal challenge test and LS means for the hyperglycemic clamp.CC BY-NC-ND · PubMed Central
Figure 2 Disposition index, M value, and M/I index before (□) and after (■) treatment with EXE, EXE+ROSI, and ROSI. *P < 0.05 when compared with baseline, †P < 0.05 between EXE+ROSI and ROSI at baseline. Data are LS means ± SE. BL, baseline; E, exenatide; E+R, exenatide plus rosiglitazone; EP, end point; I, steady-state plasma insulin concentration during the euglycemic clamp; M, insulin-stimulated glucose disposal during the euglycemic clamp; R, rosiglitazone.
Figure 2 Disposition index, M value, and M/I index before (□) and after (■) treatment with EXE, EXE+ROSI, and ROSI. *P < 0.05 when compared with baseline, †P < 0.05 between EXE+ROSI and ROSI at baseline. Data are LS means ± SE. BL, baseline; E, exenatide; E+R, exenatide plus rosiglitazone; EP, end point; I, steady-state plasma insulin concentration during the euglycemic clamp; M, insulin-stimulated glucose disposal during the euglycemic clamp; R, rosiglitazone.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 106

Metadata

Authors
DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Eli Lilly (United States) (US)
  • Amylin Pharmaceuticals, San Diego, California.
Corresponding author
DeFronzo, Ralph A.
Venue
Diabetes Care
Published
2010-01-27
Volume
33
Issue
5
Pages
951-957
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2105926302
Cited by
104
References
25
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 9 · 2016: 10 · 2015: 6 · 2014: 13 · 2013: 13 · 2012: 16
FWCI
11.58
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
exenatide, rosiglitazone, type 2 diabetes, metformin, combination therapy, beta-cell function, insulin secretion, insulin sensitivity, glycemic control, weight gain, weight loss, insulin resistance
MeSH terms
Rosiglitazone, Exenatide, Insulin Secretion, Aged, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Insulin Resistance, Male, Metformin, Middle Aged, Peptides, Venoms, Glucose Clamp Technique, Weight Gain, Treatment Outcome, Thiazolidinediones, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.